For many years, tolvaptan has been the only approved treatment shown to slow the progression of ADPKD. But the research landscape is changing. Scientists are studying new treatments that target PKD in different ways, with the goal of slowing, stopping, or even reversing the disease.
In this new overview, Dr. Chris Chen, Vice President of Research Programs at the PKD Foundation, takes a closer look at the ADPKD clinical trial pipeline and the promising therapies being studied today. He explains what researchers are learning and what these advances could mean for the future of people living with ADPKD.